Navigation Links
Tackling Atrial Fibrillation and Associated Cardiovascular Risk
Date:11/4/2008

- RecordAF Registry Baseline Data and New Data from the Landmark ATHENA

Study
PARIS, Nov. 4 /PRNewswire/ --

Live Webcast Media Briefing - non-US media only

Wednesday 12 November 2008 - 14.00-15.00am CET

Background:

-- AF is a growing health concern directly responsible for increased

morbidity and mortality

-- There is a need for a global prospective database like RecordAF, which

takes a closer look at disease characteristics and how management of AF

affects cardiovascular (CV) outcomes

-- AF is associated with a high hospitalization burden - 70 percent of AF

management costs are driven by hospitalization costs (Ringborg et al.

Europace 2008; 10:403-11)

-- A further sub-analysis of the ATHENA trial was conducted:

-- to better understand the impact of dronedarone on hospitalization

of AF patients particularly on the number and duration of CV and

non CV hospitalization nights

-- An additional sub-analysis was also conducted to further explore

dronedarone's rhythm and rate controlling properties

-- The ATHENA study is the first AF trial designed to evaluate the effect

of an anti arrhythmic drug (AAD) on morbidity and mortality. It showed

that dronedarone (brand name Multaq(R)), a new AAD undergoing the

registration process, can significantly improve CV outcomes including

reducing the risk of hospitalization and death.

Register on-line in advance of the online event:

1. Go to https://sanofiaventismediabriefing.webex.com/sanofiaventismediabriefing/ons t age/g.php?d=702842657&t=a&EA=nburns%40webex.com&ET=6b1f2c181b8fa5176928ed1c 72 009c4d&ETR=8789fb6f20765cb360e4d0c88cea0f23 (due to the length of this URL, please copy and paste it into your browser)

2. Click "Register"

3. On the registration form, enter your information then click "Submit"

Once the host approves your registration, you will receive a confirmation email containing instructions on how to join the event (event number and password) on the day of the announcement.

Once logged on, you will also be required to connect to a teleconference in order to participate in the live Q&A session with panelists at the end of the event.

Teleconference dial in number (toll-free):

1) To obtain your teleconference number, register first by following the instructions above.

2) Once connected, a pop-up window will appear

3) Select country of affiliation to obtain local dial-in number

4) Dial-in and enter your login details using the provided number within the pop-up window

Please ensure you log on to the event 15 minutes before the start time so as not to miss valuable information.

IMPORTANT NOTICE:

This event is not part of the official Scientific Sessions 2008 as planned by the AHA Committee on Scientific Sessions Programming


'/>"/>
SOURCE Sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
2. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
3. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
4. Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinical Studies
5. American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
6. Multaq(R) (dronedarone) Granted FDA Priority Review for Patients with Atrial Fibrillation
7. Studies of an Innovative Catheter Ablation System for Atrial Fibrillation Reveal Excellent Outcomes, Safety Profile and Fast Procedure Times
8. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
9. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
10. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
11. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017  Maxor National Pharmacy Services, LLC ("Maxor"), a ... named Leah Bailey as General Counsel.  Bailey will ... company. With more than 13 years of ... focused on health care, Bailey joins the Maxor team ... Bailey advised the PBM, Specialty, and Mail Order business ...
(Date:3/29/2017)... , March 29, 2017  Designers of primary ... reduce solution size by 50% and extend battery life ... power management integrated circuit (PMIC) from Maxim Integrated Products, ... supports a low input voltage of just 0.7V for ... and Silver Oxide, as well as the more common ...
(Date:3/29/2017)... Stryker announced today that it has been ... partnership with Great Place to Work (GPTW). We ranked ... list highlights the top U.S. companies with 1,000 or ... demonstrating respect, compassion and concern for their employees, their ... the companies on the list, GPTW asked more than ...
Breaking Medicine Technology:
(Date:3/29/2017)... , ... March 29, 2017 ... ... Alliance (GRMA) is growing as it continues developing an ANSI-approved, consensus-based American ... The organization, which plans to publish the first ANSI-approved GMP standard for ...
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a ... the finalization of the company’s executive management team with prominent executives from both inside ... Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who has more than twenty ...
(Date:3/29/2017)... ... March 29, 2017 , ... The assembly of synthetic ... involve many repetitive steps and often scientists require many different versions of DNA. ... and results in a lower error rate and cost saving for reagents and ...
(Date:3/29/2017)... PITTSBURGH, PA (PRWEB) , ... ... ... the eastern suburbs and South Hills of Pittsburgh now have easier access ... western Pennsylvania only by Allegheny Health Network (AHN). Orthopaedic surgeons at Forbes ...
(Date:3/29/2017)... ... ... AvePoint , the Microsoft Cloud expert, is pleased to announce the ... the Riverfront Plaza, 901 East Byrd Street. AvePoint is celebrating with a ribbon-cutting ceremony ... Mayor of Richmond Levar M. Stoney. , Founded in 2001, AvePoint employs more than ...
Breaking Medicine News(10 mins):